Twist Bioscience Stock News

Twist Bioscience Corporation (NASDAQ: TWST) reported a 17% Y/Y increase in its Q4 revenues to $37.95 million, beating the Wall Street estimate of $37.02 million, driven by strength in SynBio, NGS, b

Twist Bioscience Co. (NASDAQ:TWST) Director Jan Johannessen sold 5,000 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 17th. The stock was sold at an average price of $115.17, for a total value of $575,850.00. The transaction was disclosed in a document filed with the SEC, which is available through this []

Twist Bioscience (TWST) delivered earnings and revenue surprises of -5% and 3.53%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience Corporation (NASDAQ:TWST)s traded shares stood at 0.72 million during the last session. At the close of trading, the stocks price was $110.62, to imply a decrease of -1.36% or -$1.53 in intraday trading. The TWST shares 52-week high remains $214.07, putting it -93.52% down since that peak but still an impressive 23.86% since Twist Bioscience Corporation (NASDAQ: TWST): Can A Stock Be -21.71% Lower Year-To-Date And Still Be A Loser? Read More »

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 10,440 shares of the stock in a transaction on Monday, November 15th. The stock was sold at an average price of $115.34, for a total transaction of $1,204,149.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Emily []

Related Stocks: TWST ,

Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AQR Capital Management LLC increased its position in Twist Bioscience Co. (NASDAQ:TWST) by 15.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 13,692 shares of the companys stock after acquiring an additional 1,801 shares during the quarter. AQR Capital Management LLCs holdings in Twist []

Both are biotech stocks with tremendous long-term opportunities.

Centogene NV (NASDAQ: CNTG) and Twist Bioscience Corporation (NASDAQ: TWST) have signed a contract to develop and commercialize custom assay kits for rare diseases. The financial details of the deal w

Twist Bioscience is a synthetic biology company that is able to produce DNA at significantly lower costs than competitors.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent bind

It could perhaps deliver a much bigger gain than 100%.